CN114886859A - Cefprozil granules - Google Patents
Cefprozil granules Download PDFInfo
- Publication number
- CN114886859A CN114886859A CN202210643138.8A CN202210643138A CN114886859A CN 114886859 A CN114886859 A CN 114886859A CN 202210643138 A CN202210643138 A CN 202210643138A CN 114886859 A CN114886859 A CN 114886859A
- Authority
- CN
- China
- Prior art keywords
- cefprozil
- pharmaceutically acceptable
- agent
- granules
- adhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 title claims abstract description 44
- 229960002580 cefprozil Drugs 0.000 title claims abstract description 44
- 239000008187 granular material Substances 0.000 title claims abstract description 25
- 239000003086 colorant Substances 0.000 claims abstract description 19
- 239000000796 flavoring agent Substances 0.000 claims abstract description 18
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 18
- 239000000853 adhesive Substances 0.000 claims abstract description 16
- 230000001070 adhesive effect Effects 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 15
- 239000003937 drug carrier Substances 0.000 claims abstract description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 11
- 229930195725 Mannitol Natural products 0.000 claims abstract description 11
- 239000000594 mannitol Substances 0.000 claims abstract description 11
- 235000010355 mannitol Nutrition 0.000 claims abstract description 11
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 11
- 229950008882 polysorbate Drugs 0.000 claims abstract description 11
- 229920000136 polysorbate Polymers 0.000 claims abstract description 11
- 125000003118 aryl group Chemical group 0.000 claims abstract description 6
- 239000000049 pigment Substances 0.000 claims abstract description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 claims abstract description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 4
- 229920002472 Starch Polymers 0.000 claims abstract description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims abstract description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims abstract description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims abstract description 4
- 239000011707 mineral Substances 0.000 claims abstract description 4
- 239000011734 sodium Substances 0.000 claims abstract description 4
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 4
- 239000008107 starch Substances 0.000 claims abstract description 4
- 235000019698 starch Nutrition 0.000 claims abstract description 4
- 229940083542 sodium Drugs 0.000 claims abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 229960001462 sodium cyclamate Drugs 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 229960001855 mannitol Drugs 0.000 claims 2
- 229940067631 phospholipid Drugs 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 206010063659 Aversion Diseases 0.000 abstract description 3
- 206010013911 Dysgeusia Diseases 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000220479 Acacia Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000520130 Enterococcus durans Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- HQXMTDSLKXAPTA-NRFANRHFSA-N diethyl (2s)-2-(hexadecanoylamino)butanedioate Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H](C(=O)OCC)CC(=O)OCC HQXMTDSLKXAPTA-NRFANRHFSA-N 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of pharmaceutical preparations and discloses cefprozil granules which comprise cefprozil, pharmaceutically acceptable pharmaceutic adjuvants and pharmaceutically acceptable carriers, wherein the pharmaceutically acceptable pharmaceutic adjuvants comprise phospholipid, mannitol and polysorbate, the pharmaceutically acceptable carriers comprise auxiliary materials comprising a disintegrating agent, an adhesive, a flavoring agent, an aromatic and a coloring agent, the disintegrating agent is one or more of carboxymethyl starch sodium, croscarmellose sodium or low-substituted hydroxypropyl cellulose, and the coloring agent is any one of phytochrome and mineral pigment. The cefprozil granules increase the solubility of the cefprozil active ingredients, improve the stability, effectively reduce the toxic and side effects of the medicament, effectively cover the bad taste of the medicament by adding the flavoring agent and the adhesive, and reduce the aversion of patients to the medicament, thereby improving the compliance of the patients, particularly children patients, in medication.
Description
Technical Field
The invention relates to the technical field of pharmaceutical preparations, in particular to cefprozil granules.
Background
Cefprozil belongs to the second generation cephalosporin antibiotics, can be used for treating bronchitis or other bacterial infections, in vitro tests prove that cefprozil has obvious effects on staphylococcus aureus, streptococcus pneumoniae and streptococcus pyogenes in gram-positive aerobic bacteria, and also has certain antibacterial activity on enterococcus durans, listeria monocytogenes, staphylococcus epidermidis, staphylococcus saprophyticus and staphylococcus warnerei.
Chinese patent CN108743548A discloses a cefprozil granule and a preparation method thereof, the cefprozil granule prepared by adopting the prescription and the process has good dissolution rate, high stability and uniform particle size, and the dissolution rate of active ingredients in the cefprozil granule is effectively improved by adding diethyl palmitoyl aspartate, but the cefprozil granule has the following defects of insolubility in water, bitter taste and large use limitation, so the cefprozil granule is provided to solve the problems.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides cefprozil granules which have the advantages of good comprehensive performance and the like, and solves the problems of insolubility in water, bitter taste and large use limitation.
(II) technical scheme
In order to achieve the purpose of good comprehensive performance, the invention provides the following technical scheme: the cefprozil granules are composed of cefprozil, pharmaceutically acceptable pharmaceutic adjuvants and pharmaceutically acceptable carriers, the pharmaceutically acceptable pharmaceutic adjuvants are composed of phospholipid, mannitol and polysorbate, and the pharmaceutically acceptable carriers are composed of auxiliary materials including a disintegrating agent, an adhesive, a flavoring agent, an aromatic and a coloring agent.
Preferably, the mass ratio of the cefprozil, the phospholipid, the mannitol and the polysorbate is as follows: 100: 125-150:100-120: 110-130.
Preferably, the mass ratio of the cefprozil, the disintegrating agent, the adhesive, the flavoring agent and the coloring agent is 100: 7-18:3-8: 25-40: 8-15.
Preferably, the disintegrant is one or more of carboxymethyl starch sodium, croscarmellose sodium or low substituted hydroxypropyl cellulose.
Preferably, the binder is one or more of xanthan gum, arabic gum, hydroxypropyl methylcellulose or povidone.
Preferably, the flavoring agent is one or more of glucose, sodium cyclamate and citric acid.
Preferably, the colorant is any one of a plant pigment and a mineral pigment.
(III) advantageous effects
Compared with the prior art, the invention provides cefprozil granules which have the following beneficial effects:
the cefprozil granules have the advantages that the solubility of the cefprozil active ingredients is improved, the stability is improved, the toxic and side effects of the medicine can be effectively reduced, the flavoring agent and the adhesive are added to effectively cover the bad taste of the medicine, and the coloring agent can reduce the aversion of patients to medicine taking, so that the compliance of the patients, particularly children patients, in medicine taking is improved.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The first embodiment is as follows:
a cefprozil granule comprises cefprozil, pharmaceutically acceptable pharmaceutic adjuvants and pharmaceutically acceptable carriers;
the pharmaceutically acceptable pharmaceutic adjuvants comprise phospholipids, mannitol and polysorbate, wherein the mass ratio of the cefprozil to the phospholipids to the mannitol to the polysorbate is 100: 125:100: 110;
the pharmaceutically acceptable carrier consists of auxiliary materials including a disintegrating agent, an adhesive, a flavoring agent, an aromatic and a coloring agent, wherein the mass ratio of the cefprozil to the disintegrating agent to the adhesive to the flavoring agent to the coloring agent is 100: 7:3: 25: 8, the disintegrating agent is carboxymethyl starch sodium, the adhesive is xanthan gum, the flavoring agent is glucose, and the coloring agent is phytochrome.
Example two:
a cefprozil granule comprises cefprozil, pharmaceutically acceptable pharmaceutic adjuvants and pharmaceutically acceptable carriers;
the pharmaceutically acceptable pharmaceutic adjuvants comprise phospholipids, mannitol and polysorbate, wherein the mass ratio of the cefprozil to the phospholipids to the mannitol to the polysorbate is 100: 135:110: 120 of a solvent;
the pharmaceutically acceptable carrier consists of auxiliary materials including a disintegrating agent, an adhesive, a flavoring agent, an aromatic and a coloring agent, wherein the mass ratio of the cefprozil to the disintegrating agent to the adhesive to the flavoring agent to the coloring agent is 100: 13:6: 35: 12, the disintegrating agent is croscarmellose sodium, the adhesive is acacia, the flavoring agent is sodium cyclamate, and the coloring agent is phytochrome.
Example three:
a cefprozil granule comprises cefprozil, pharmaceutically acceptable pharmaceutic adjuvants and pharmaceutically acceptable carriers;
the pharmaceutically acceptable pharmaceutic adjuvants comprise phospholipid, mannitol and polysorbate, wherein the mass ratio of the cefprozil to the phospholipid to the mannitol to the polysorbate is as follows: 100: 150:120: 130;
the pharmaceutically acceptable carrier consists of auxiliary materials including a disintegrating agent, an adhesive, a flavoring agent, an aromatic and a coloring agent, wherein the mass ratio of the cefprozil to the disintegrating agent to the adhesive to the flavoring agent to the coloring agent is 100: 18:8: 40: 15, disintegrating agent is low substituted hydroxypropyl cellulose, adhesive is polyvidone, taste correcting agent is citric acid, and coloring agent is mineral pigment.
The invention has the beneficial effects that: the dissolution performance of the cephalosporin active ingredients is increased, the stability is improved, the toxic and side effects of the medicament can be effectively reduced, the bad taste of the medicament can be effectively covered by adding the flavoring agent and the adhesive, and the aversion to the medicament taking of a patient can be reduced by adding the coloring agent, so that the medicament compliance of the patient, particularly a child patient, is improved.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (7)
1. The cefprozil granules are characterized in that: the granules comprise cefprozil, pharmaceutically acceptable pharmaceutic adjuvants and pharmaceutically acceptable carriers, wherein the pharmaceutically acceptable pharmaceutic adjuvants comprise phospholipid, mannitol and polysorbate, and the pharmaceutically acceptable carriers comprise adjuvants comprising a disintegrating agent, an adhesive, a flavoring agent, an aromatic and a coloring agent.
2. The cefprozil granule as claimed in claim 1, wherein the mass ratio of cefprozil, phospholipid, mannitol and polysorbate is 100: 125-150:100-120: 110-130.
3. The cefprozil granule formulation according to claim 1, wherein the mass ratio of cefprozil, disintegrant, binder, flavoring agent and coloring agent is 100: 7-18:3-8: 25-40: 8-15.
4. The cefprozil granule formulation according to claim 1, wherein the disintegrant is one or more of carboxymethyl starch sodium, croscarmellose sodium or low substituted hydroxypropylcellulose.
5. The cefprozil granule formulation according to claim 1, wherein the binder is one or more of xanthan gum, arabic gum, hydroxypropyl methylcellulose or povidone.
6. The cefprozil granule formulation according to claim 1, wherein the flavoring agent is one or more of glucose, sodium cyclamate and citric acid.
7. The cefprozil granule formulation according to claim 1, wherein the colorant is any one of phytochrome and mineral pigment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210643138.8A CN114886859A (en) | 2022-06-09 | 2022-06-09 | Cefprozil granules |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210643138.8A CN114886859A (en) | 2022-06-09 | 2022-06-09 | Cefprozil granules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114886859A true CN114886859A (en) | 2022-08-12 |
Family
ID=82728642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210643138.8A Pending CN114886859A (en) | 2022-06-09 | 2022-06-09 | Cefprozil granules |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114886859A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953790A (en) * | 2010-06-17 | 2011-01-26 | 王丽燕 | Granules comprising cefprozil lipidosome and preparation method thereof |
| CN101966154A (en) * | 2010-07-05 | 2011-02-09 | 王丽燕 | Granular formulation containing cefixime liposomes and preparation method thereof |
| WO2011093828A2 (en) * | 2010-01-29 | 2011-08-04 | Mahmut Bilgic | Solid dosage forms comprising cefprozil |
| CN108743548A (en) * | 2018-06-28 | 2018-11-06 | 苏州中联化学制药有限公司 | A kind of Cefprozil granule and preparation method thereof |
-
2022
- 2022-06-09 CN CN202210643138.8A patent/CN114886859A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011093828A2 (en) * | 2010-01-29 | 2011-08-04 | Mahmut Bilgic | Solid dosage forms comprising cefprozil |
| CN101953790A (en) * | 2010-06-17 | 2011-01-26 | 王丽燕 | Granules comprising cefprozil lipidosome and preparation method thereof |
| CN101966154A (en) * | 2010-07-05 | 2011-02-09 | 王丽燕 | Granular formulation containing cefixime liposomes and preparation method thereof |
| CN108743548A (en) * | 2018-06-28 | 2018-11-06 | 苏州中联化学制药有限公司 | A kind of Cefprozil granule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1446010B1 (en) | Stabilized azithromycin compositions | |
| EP3135289B1 (en) | Tetracycline compositions | |
| WO2011093823A2 (en) | Effervescent formulations comprising cefaclor and clavulanic acid | |
| CN101198319B (en) | Granular preparation containing biguanide compound | |
| ES2202069T3 (en) | PROCEDURE FOR THE PREPARATION OF A BIODAVAILABLE ORAL DOSAGE FORM OF AXETIL CEFUROXIMA. | |
| CN103393617B (en) | Febustat tablet and preparation method thereof | |
| US20180078646A1 (en) | Tigecycline composition for injection | |
| JP2023529033A (en) | Bendamustine composition and use thereof | |
| CN101658677A (en) | Lovastatin-sulfobutyl ether-beta-cyclodextrin inclusion compound, preparation and preparation method thereof | |
| CN114886859A (en) | Cefprozil granules | |
| CN101890006A (en) | Amoxicillin sustained-release preparation composition and preparation method thereof | |
| EP2277546B1 (en) | Stable ready to use injectable paracetamol formulation | |
| WO2015071299A2 (en) | Stable pharmaceutical compositions | |
| KR20150102852A (en) | Solid dispersion composition with increased stability comprising amorphous solifenacin or pharmaceutically acceptable salts thereof | |
| CN102525982A (en) | Stable moxifloxacin hydrochloride medicinal composition | |
| CN111732593A (en) | Piperazine oxide derivative and composition, preparation method and application thereof | |
| CN111574518A (en) | Pyridine oxide derivative and composition, preparation method and application thereof | |
| CN110396102A (en) | Cefoxitin sodium pharmaceutical preparation is in vaginal hysterectomy, abdominal cavity uterectomy, the preoperative prevention infection application of (palace) production of cutting open the belly | |
| CN108685869A (en) | A kind of clarithromycin capsule | |
| CN109010294A (en) | A kind of production technology of Cefditoren pivoxil Cephalosporins tablet | |
| WO2023165050A1 (en) | Stable depsipeptide pharmaceutical composition | |
| CN117503718A (en) | Preparation for sublingual administration of Enlicarpa and preparation method thereof | |
| CN102342939B (en) | Application of berberine-phenylacetic acid derivatives or their salts in preparing medicaments treating antimicrobial infection | |
| CN112535667A (en) | Lacosamide dry syrup and preparation method thereof | |
| CN103446056B (en) | Pharmaceutical composition containing ceftizoxime sodium and pediatric compound amino acid injection (19AA-I) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220812 |